AccurKardia’s launch of a multicenter pilot study for its AI-powered AK+ GuardTM technology marks a significant advancement in the early detection of hyperkalemia, a condition that can have serious health implications. This initiative not only underscores the growing role of artificial intelligence in healthcare but also aims to improve patient outcomes across various care settings.
NEW YORK–(BUSINESS WIRE)– #AIinHealthcare–AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ GuardTM, an FDA Breakthrough Device Designated AI-powered technology that enables the detection of hyperkalemia using Lead I ECG. The three-arm prospective pilot study will evaluate more than 150 patients across inpatient, outpatient and home settings in the U.S. Hyperkalemia, or an excess of serum potassium in the blood, is a common condi
Source: Original Press Release